232 related articles for article (PubMed ID: 19299322)
1. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers.
Lei HP; Wang G; Wang LS; Ou-yang DS; Chen H; Li Q; Zhang W; Tan ZR; Fan L; He YJ; Zhou HH
Ann Pharmacother; 2009 Apr; 43(4):726-31. PubMed ID: 19299322
[TBL] [Abstract][Full Text] [Related]
2. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.
Wang G; Lei HP; Li Z; Tan ZR; Guo D; Fan L; Chen Y; Hu DL; Wang D; Zhou HH
Eur J Clin Pharmacol; 2009 Mar; 65(3):281-5. PubMed ID: 18982321
[TBL] [Abstract][Full Text] [Related]
3. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
4. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism.
Shi HY; Yan J; Zhu WH; Yang GP; Tan ZR; Wu WH; Zhou G; Chen XP; Ouyang DS
Eur J Clin Pharmacol; 2010 Nov; 66(11):1131-6. PubMed ID: 20669013
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.
Jiang T; Rong Z; Xu Y; Chen B; Xie Y; Chen C; Lu Y; Shen Y; Li H; Sun J; Chen H
Clin Drug Investig; 2013 Jan; 33(1):1-9. PubMed ID: 23179471
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole.
Yin OQ; Tomlinson B; Waye MM; Chow AH; Chow MS
Pharmacogenetics; 2004 Dec; 14(12):841-50. PubMed ID: 15608563
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.
Yu BN; Chen GL; He N; Ouyang DS; Chen XP; Liu ZQ; Zhou HH
Drug Metab Dispos; 2003 Oct; 31(10):1255-9. PubMed ID: 12975335
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.
Wang JH; Liu ZQ; Wang W; Chen XP; Shu Y; He N; Zhou HH
Clin Pharmacol Ther; 2001 Jul; 70(1):42-7. PubMed ID: 11452243
[TBL] [Abstract][Full Text] [Related]
10. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics.
Rengelshausen J; Banfield M; Riedel KD; Burhenne J; Weiss J; Thomsen T; Walter-Sack I; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2005 Jul; 78(1):25-33. PubMed ID: 16003289
[TBL] [Abstract][Full Text] [Related]
11. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
Ko JW; Jang IJ; Shin JG; Nam SK; Shin SG; Flockhart DA
Clin Pharmacol Ther; 1999 Jun; 65(6):606-14. PubMed ID: 10391666
[TBL] [Abstract][Full Text] [Related]
12. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children.
Narita A; Muramatsu H; Sakaguchi H; Doisaki S; Tanaka M; Hama A; Shimada A; Takahashi Y; Yoshida N; Matsumoto K; Kato K; Kudo K; Furukawa-Hibi Y; Yamada K; Kojima S
J Pediatr Hematol Oncol; 2013 Jul; 35(5):e219-23. PubMed ID: 23588332
[TBL] [Abstract][Full Text] [Related]
13. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.
Hassan A; Burhenne J; Riedel KD; Weiss J; Mikus G; Haefeli WE; Czock D
Ther Drug Monit; 2011 Feb; 33(1):86-93. PubMed ID: 21192313
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.
Ikeda Y; Umemura K; Kondo K; Sekiguchi K; Miyoshi S; Nakashima M
Clin Pharmacol Ther; 2004 Jun; 75(6):587-8. PubMed ID: 15179414
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.
Damle B; Varma MV; Wood N
Antimicrob Agents Chemother; 2011 Nov; 55(11):5172-7. PubMed ID: 21876043
[TBL] [Abstract][Full Text] [Related]
17. Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.
Grün B; Merkel U; Riedel KD; Weiss J; Mikus G
Br J Clin Pharmacol; 2012 Nov; 74(5):854-63. PubMed ID: 22381043
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole and fluconazole increase the exposure to oral diazepam.
Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.
Weiss J; Ten Hoevel MM; Burhenne J; Walter-Sack I; Hoffmann MM; Rengelshausen J; Haefeli WE; Mikus G
J Clin Pharmacol; 2009 Feb; 49(2):196-204. PubMed ID: 19033450
[TBL] [Abstract][Full Text] [Related]
20. [The polymorphism of cytochrome P(450) 2C19 gene in patients with invasive fungal infections.].
Wu JQ; Zhu LP; Ou XT; Xu B; Zhang QQ; Weng XH
Zhonghua Nei Ke Za Zhi; 2010 Feb; 49(2):138-41. PubMed ID: 20356512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
